Key takeaways
Riluzole (Rilutek) and edaravone (Radicava) are both medications used to treat amyotrophic lateral sclerosis (ALS), a condition that affects nerve cells in the brain and spinal cord. While they share this indication, they differ in several ways. Riluzole is a glutamate antagonist that helps slow the progression of ALS by reducing glutamate levels, and it is available in tablet, liquid, and oral film forms. Edaravone, on the other hand, is thought to have antioxidant properties and is available as an intravenous infusion or oral suspension. Riluzole is typically taken twice a day, while edaravone follows a more complex dosing schedule with cycles of daily doses followed by breaks. Riluzole is available as a lower-cost generic for the tablet form, whereas edaravone is only available as a brand-name medication, which can be expensive. Common side effects of riluzole include mouth numbness and nausea, while edaravone can cause headaches and skin irritation. Additionally, edaravone carries a risk of severe allergic reactions, especially in those with sulfite allergies.
